Mohamed Elemary

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Oncology · 2015 · 363 citations

Medicine, Hematology, Immunology +17

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Fredrik Schjesvold, Albert Oriol, Lionel Karlin et al. · The Lancet Haematology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacology +11

Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an <scp>MDS</scp>‐<scp>CAN</scp> prospective study

Rena Buckstein, Richard A. Wells, Nancy Zhu et al. · British Journal of Haematology · 2016 · 97 citations · Full text

Medicine, Biostatistics, Frailty +16

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Haematology · 2020 · 96 citations

Life Sciences, Hematology, Immunology +12